Dr. Juan Granada, New President and CEO of the Cardiovascular Research Foundation

The prestigious Colombian Interventional Cardiologist was appointed President and Chief Executive Officer (CEO) of the Cardiovascular Research Foundation (CRF) 15 days ago. He is now also a member of the CRF board of Directors.

Dr. Juan Granada, New President and CEO of the Cardiovascular Research Foundation

SOLACI wishes Dr. Granada congratulations for this well deserved recognition and wishes him the best for the important challenge ahead. We are sure his experience and leadership will promote CRF sustained growth, to consolidate as one of the world’s referents in terms of interventional cardiology.

 

We also take this opportunity to thank the unconditional support and tireless collaboration of Dr. Granada towards SOLACI all these years. We hope to strengthen the ties between both organizations, to generate new initiatives and joint actions to keep fostering the development of interventional cardiology in Latin America and the rest of the world.  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

SELUTION Sirolimus-Eluting Balloon For De Novo Coronary Lesions – New Evidence and Clinical Perspectives

The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest evidence and clinical perspectives...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....